Recombinant Human IL31 Protein，His

Interleukin 31 (IL-31) is a cytokine primarily produced by activated T-helper cells and plays a significant role in allergic inflammation and immune responses. Research has shown that IL-31 is notably involved in various dermatological conditions, particularly pruritus (itching) associated with atopic dermatitis and other skin disorders. The signaling pathway of IL-31, primarily through its receptor IL-31RA, activates various downstream pathways that lead to the activation of neurons and the subsequent sensation of itch, making it a critical target for therapeutic intervention. Recombinant IL-31 proteins have become crucial tools in understanding the cytokine's role in immune modulation and neurogenic inflammation. By producing IL-31 in a recombinant form, researchers have been able to study its effects on immune cells, skin models, and even animal models of allergic diseases. The investigation into IL-31 functions has unveiled its involvement not just in cutaneous conditions but also in systemic inflammatory responses. Given the rising prevalence of allergic diseases globally, targeting IL-31 with monoclonal antibodies or other inhibitory agents has emerged as a promising strategy for developing new treatments aimed at alleviating symptoms related to itching and inflammation, thereby improving the quality of life for patients suffering from these chronic conditions. Thus, ongoing research into IL-31 recombinant proteins is pivotal for advancing our understanding of immune mechanisms and for the development of novel therapeutic approaches to manage allergic and inflammatory diseases effectively.